Tyrosinase as an autoantigen in patients with vitiligo

Clinical and Experimental Immunology

Volumn 105, Issue 1, 1996, Pages 84-88

  Baharav, E ^a   Merimski, O ^a,b   Shoenfeld, Y ^c   Zigelman, R ^a   Gilbrud, B ^c   Yecheskel, G ^a   Youinou, P ^d   Fishman, P ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d BREST UNIVERSITY HOSPITAL   (France)

Author keywords

autoantibodies; autoimmunity; tyrosinase; vitiligo

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; MONOPHENOL MONOOXYGENASE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MELANOCYTE; MELANOGENESIS; PRIORITY JOURNAL; VITILIGO;

EID: 0030035537     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.d01-727.x     Document Type: Article

References (43)

1. Nordlund JJ, Lerner AB. Vitiligo: it is important. (Editorial). Arch Dermatol 1982; 18:5-8.
2. McBurney EL. Vitiligo: clinical picture and pathogenesis. Arch Intern Med 1979; 139:1295-7.
3. Moellmann GE, Krass P, Halaban R. On the subject of serum antibodies to melanocytes. J Invest Dermatol 1985; 84:333-4.
4. Galbraith GMP, Miller D, Emerson DL. Western blot analysis of serum antibody reactivity with human melanoma cell antigens in alopecia areata and vitiligo. Clin Immunopathol 1988; 48:317-24.
5. Naughton G, Reggiardo D, Bystryn JC. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 1986; 15:978-81.
6. Naughton GK, Eisinger M, Bystryn JC. Antibodies to normal human melanocytes in vitiligo. J Exp Med 1983; 158:246-51.
7. Hertz KC, Gazze LA, Charles AB, Kirkpatrick H, Katz SI. Autoimmune vitiligo-detection of antibodies to melanin producing cells. New Engl J Med 1977; 297:634-7.
8. El Mofty A, El Morf M. Vitiligo: a symptom complex. Int J Dermatol 1980; 19:237-44.
9. Macron C, Winter KI, Traisman HS. Vitiligo and juvenile diabetes melitus. Arch Dermatol 1977; 113:1515-9.
10. Harzoulis P, Kanakoudi-Tsakalidis F, Uyzantiadis A. Autoimmunity and vitiligo (abstract). Arch Dermatol 1970; 114:1554-60.
11. Bettere C, Del Prete GF, Preserico A, Bersani G, Ciracciolo F, Trisotto A, Poggy F. Autoantibodies in vitiligo. Arch Dermatol 1976; 112:1328.
12. Brostoff J, Bor S, Feiwel M. Autoantibodies in patients with vitiligo. Lancet 1969; 2:177.
13. Grimes PF, Halder R, Jones C. Autoantibodies and their clinical significance in black vitiligo population. Arch Dermatol 1983; 119:300-3.
14. Dunston GM, Halder RM. Vitiligo is associated with HLA-DR4 in black patients: a preliminary report. Arch Dermatol 1990; 126:56-60.
15. Poloy A, Tibor L, Kramer J, Anh-Tuan N, Kraszite E. HLA-DR1 is associated with vitiligo. Immunol Letters 1991; 27:59-62.
16. Foley LM, Lowe NJ, Mischelhoff E, Tiwari JL. Association of HLA-DR4 with vitiligo. J Am Acad Dermatol 1983; 8:39-42.
17. Naughton G, Reggiardo D, Bystryn JC. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 1989; 15:978.
18. Fishman P, Azizi E, Shoenfeld Y et al. Vitiligo antibodies are effective against melanoma. Cancer 1993; 72:8-15.
19. Merimsky O, Shoenfeld Y, Yecheskel G, Chaichik S, Azizi E, Fishman P. Vitiligo and melanoma associated hypopigmentation: a similar appearance but different mechanisms. Cancer Immunol 1994;38:411-6.
20. Cui J, Harning R, Henn M, Bystryn JC. Identification of pigment cell antigen defined by vitiligo antibodies. J Invest Dermatol 1992; 98: 162-5.
21. Song YH, Connor E, Li Y, Zorovich B, Maclaren N. The role of tyrosinase in autoimmune vitiligo. Lancet 1994; 344:1049-52.
22. Norris DA, Kissinger RM, Naughton GM, Bystryn JC. Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complementmediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol 1988; 90:783-9.
23. Shibahara S, Tomita Y, Sakahura T, Nagar C, Chaudhuri B, Muller R. Cloning and expression of DNA encoding mouse tyrosinase. Nucleic Acids Res 1986; 14:2413-27.
24. Jimenez M, Lee Maloy W, Hearing VJ. Specific identification of an authentic clone for mammalian tyrosinase. J Biol Chem 1989; 264:3397-403.
25. Yamamato H, Takeuchi S, Kudo T, Sato C, Takeuchi T. Melanin production in culture albino melanocytes transfected with mouse tyrosinase cDNA. Jap J Genet 1989; 64:121-35.
26. Wittbjer A, Odh G, Rosengren AM, Rorsman H. Isolation of soluble tyrosinase from human melanoma. Acta Derm Venereol (Stokholm) 1990; 70:291-4.
27. Karg E, Hultberg B, Isaksson A, Rosengren E, Rorsman H. Enzyme release from cultured human melanoma cells. Acta Derm Venereol (Stokholm) 1990; 70:286-90.
28. Sohn N, Gang H, Gumport SL, Goldstein M, Depisch LM. Generalized melanosis secondary to malignant melanoma. Cancer 1969; 24:897-903.
29. Nishioka K, Romsdahl MM, McMurtrey MJ. Adaptation of triatiated tyrosinase assay to serum tyrosinase and its specific elevation in melanoma. In: Klaus SN, ed. Pigmented cell 1979; 5:300-4.
30. Agrup P, Carstam R, Wittbjer A, Rorsman H, Tosengren E. Tyrosinase activity in serum from patients with malignant melanoma. Acta Derm Venereon (Stokholm) 1989; 69:120-4.
31. Al Badri AMT, Foulis AK, Todd PM, Garioch JJ, Gudgeon JE, Slewart DG, Gracie JA, Goudie RB. Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo. J Pathol 1993; 169:203-6.
32. Le Poole IC, Mutis T, van den Wijngaard R, Westerhof W, Ottenhoff T, de Vries A, Das PK. A novul, antigen-presenting function of melanocytes and its possible relationship to hypopigmentary disorders. J Immunol 1993; 151:7284-92.
33. Devey ME, Bleasdale K, Lee S, Rath S. Determination of functional affinity of IgG1 and IgG4 antibodies to tetanus toxoid by isotype-specific solid-phase assay. J Immunol Methods 1988; 106:119-25.
34. Youinou P, Keusch J, Casbrun-Budd R, Paolozzi L, Lamour A, Le Goff P, Bendauod B. Tiopronine induced reduction of rheumatoid factor functional affinity and asialylated IgG in patients with rheumatoid arthritis. Clin Exp Rheumatol 1992; 10:333-8.
35. Tomer Y, Gilburd B, Blank M et al. Characterization of biologically active ANCA induced in mice: pathogenetic role in experimental vasculitis. Arthritis Rheum 1995; 38:1375-81.
36. Harning R, Cui J, Bystryn JC. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 1991; 97:1078-80.
37. Karg E, Jultberg B, Isakson A, Rosengren E, Rorsman H. Enzyme release from culture human melanoma cells. Acta Derm Venereol 1990; 70:268-90.
38. Nishioka K, Romsdahl MM, McMurtery MJ. Adaptation of tritiated tyrosinase assay to serum tyrosinase and its specific elevation in melanoma. Pigment Cell 1979; 5:300-4.
39. Bouchard B, Vijayasaradhi S, Houghton AN. Production and characterization of antibodies against human tyrosinase. J Invest Dermatol 1994; 102:291-5.
40. Baharav E, Merinsky O, Shoenfeld Y, Altomonte M, Maio M, Ferrone S, Fishman P. Anti-tyrosinase antibodies participate in the immune response to vaccination with anti-idiotypic antibodies mimicking the high molecular weight melanoma associated antigen. Melanoma Research 1995; 5:337-48.
41. Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plean E, Lethe' B, Coulie P, Boon T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocites on HLA-A2 melanoma. J Exp Med 1993; 178:489-95.
42. Jolley RL Jr, Robb DA, Mason HS. The multiple forms of mushroom tyrosinase. J. Biol Chem 1969; 244:1593-9.
43. Wittbjer A, Odh G, Rosengren AM, Rosengren E, Rorsman H. Isolation of soluble tyrosinase from human melanoma cells. Acta Derm Venereol 1990; 70:291-4.